NervGen Pharma Corp
OTCQB:NGENFView on Canadian Exchange

  • LAST PRICE
    1.7000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 1.7000
  • Day Range
    ---
  • 52 Week Range
    1.1600
    2.9900
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Jun 6, 2024

      Show headlines and story abstract

    • 6:01PM ET on Thursday Jun 06, 2024 by Newsfile
      Companies Mentioned: NGENF

      Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive stock options to directors and consultants of the company exercisable at a price of $1.79 per share (the "Options"). 400,000 of the Options are exercisable for a period of five years and vest equally every three months over a one-year period and 550,000 of the Options are exercisable for a period of ten years and vest equally every six months over a two-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan.

    • 6:01PM ET on Thursday Jun 06, 2024 by Dow Jones
      Companies Mentioned: NGEN

      Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive stock options to directors and consultants of the company exercisable at a price of $1.79 per share (the "Options"). 400,000 of the Options are exercisable for a period of five years and vest equally every three months over a one-year period and 550,000 of the Options are exercisable for a period of ten years and vest equally every six months over a two-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan.

  • Jun 5, 2024

  • May 17, 2024

Peers Headlines

No documents available